Natco Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE987B01026
  • NSEID: NATCOPHARM
  • BSEID: 524816
INR
817.00
-4.5 (-0.55%)
BSENSE

Nov 20

BSE+NSE Vol: 6.23 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 156274,
    "name": "Natco Pharma",
    "stock_name": "Natco Pharma",
    "full_name": "Natco Pharma Ltd.",
    "name_url": "stocks-analysis/natco-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "817.00",
    "chg": -4.5,
    "chgp": "-0.55%",
    "dir": -1,
    "prev_price": "821.50",
    "mcapval": "16,177.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524816,
    "symbol": "NATCOPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE987B01026",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "6.23 lacs",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/natco-pharma-156274-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Natco Pharma Ltd: Valuation Shifts Signal Changing Price Attractiveness Amid Sector Dynamics",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/natco-pharma-ltd-valuation-shifts-signal-changing-price-attractiveness-amid-sector-dynamics-4264501",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/NatcoPharmaLtd_valuationdot_4264501.png",
        "date": "2026-11-17 08:00:08",
        "description": "Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, signalling a notable change in price attractiveness. This article analyses the recent valuation metrics, compares them with peer averages, and examines the implications for investors amid evolving market dynamics."
      },
      {
        "title": "Natco Pharma Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/natco-pharma-ltd-is-rated-sell-by-marketsmojo-4260686",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/NatcoPharmaLtd_mojoScore_4260686.png",
        "date": "2026-11-13 10:10:45",
        "description": "Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 November 2026, providing investors with the latest insights into the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Natco Pharma Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/natco-pharma-ltd-is-rated-sell-by-marketsmojo-4247304",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/NatcoPharmaLtd_mojoScore_4247304.png",
        "date": "2026-11-02 10:10:25",
        "description": "Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Natco Pharma Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/natco-pharma-ltd-is-rated-sell-by-marketsmojo-4233448",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/NatcoPharmaLtd_mojoScore_4233448.png",
        "date": "2026-10-22 10:10:26",
        "description": "Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 4 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Natco Pharma Ltd. Falls to 52-Week Low of Rs 780 as Sell-Off Deepens",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/natco-pharma-ltd-stock-falls-to-52-week-low-of-rs780-4226265",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/NatcoPharmaLtd_priceRelatedfactors_4226265.png",
        "date": "2026-10-15 09:40:20",
        "description": "For the third consecutive session, Natco Pharma Ltd. has seen its share price decline, culminating in a fresh 52-week low of Rs 780 on 15 Oct 2026. This downward momentum has dragged the stock below all key moving averages, signalling persistent selling pressure despite a broader market that is showing signs of resilience."
      },
      {
        "title": "Natco Pharma Ltd. Falls to 52-Week Low of Rs 784.2 as Sell-Off Deepens",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/natco-pharma-ltd-stock-hits-52-week-low-at-rs7842-amidst-continued-downtrend-4225739",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/NatcoPharmaLtd_priceRelatedfactors_4225739.png",
        "date": "2026-10-14 13:08:16",
        "description": ""
      },
      {
        "title": "Natco Pharma Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/natco-pharma-ltd-is-rated-sell-by-marketsmojo-4221806",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/NatcoPharmaLtd_mojoScore_4221806.png",
        "date": "2026-10-11 10:10:15",
        "description": "Natco Pharma Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 October 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Natco Pharma Ltd. Technical Momentum Shifts to Bearish Amid Market Pressure",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/natco-pharma-ltd-technical-momentum-shifts-to-bearish-amid-market-pressure-4217949",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/NatcoPharmaLtd_technicaldot_4217949.png",
        "date": "2026-10-08 08:00:22",
        "description": "Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. This change is underscored by deteriorating signals across key technical indicators including MACD, RSI, Bollinger Bands, and moving averages, reflecting growing market caution despite the company’s resilient price levels relative to broader indices."
      },
      {
        "title": "Natco Pharma Ltd. Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/natco-pharma-ltd-technical-momentum-shifts-amid-mixed-market-signals-4215078",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/NatcoPharmaLtd_technicaldot_4215078.png",
        "date": "2026-10-06 08:00:44",
        "description": "Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend. Despite a marginal day change of 0.05% with the stock closing at ₹822.15, the technical indicators present a complex picture that investors should carefully analyse before making decisions."
      }
    ],
    "total": 82,
    "sid": "156274",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/natco-pharma-156274"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "20-Nov-2026",
      "details": "Press Release regarding the receipt of Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) Inspection at our Visakhapatnam Andhra Pradesh Finished Dosage Formulations (FDF) Unit",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "18-Nov-2026",
      "details": "Q2FY27 Earnings Conference Call Transcript",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "16-Nov-2026",
      "details": "Intimation of Investor Meet",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Natco Pharma Ltd. has declared <strong>62%</strong> dividend, ex-date: 19 Nov 26",
          "dt": "2026-11-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Natco Pharma Ltd. has announced <strong>2:10</strong> stock split, ex-date: 26 Nov 15",
          "dt": "2015-11-26",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Natco Pharma Ltd. has announced <strong>2:21</strong> rights issue, ex-date: 01 Oct 26",
          "dt": "2026-10-01",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Press Release / Media Release

20-Nov-2026 | Source : BSE

Press Release regarding the receipt of Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) Inspection at our Visakhapatnam Andhra Pradesh Finished Dosage Formulations (FDF) Unit

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

18-Nov-2026 | Source : BSE

Q2FY27 Earnings Conference Call Transcript

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

16-Nov-2026 | Source : BSE

Intimation of Investor Meet

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Natco Pharma Ltd. has declared 62% dividend, ex-date: 19 Nov 26

stock-summary
SPLITS

Natco Pharma Ltd. has announced 2:10 stock split, ex-date: 26 Nov 15

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

Natco Pharma Ltd. has announced 2:21 rights issue, ex-date: 01 Oct 26